Introduction {#sec1_1}
============

Retroperitoneal liposarcoma is a rare neoplasia that accounts for 10--15% of the soft-tissue tumors \[[@B1], [@B2], [@B3]\]. The annual incidence is approximately 2.7 cases/million inhabitants \[[@B4]\]. Well-differentiated (WD) liposarcoma is the most common subtype, besides being the one with the slowest and more gradual progression \[[@B5]\].

The histologic subtype, growth rate, and size of the tumor are independent predictors for survival, specifically for liposarcomas, besides influencing the time to recurrence after surgical extraction \[[@B6], [@B7], [@B8]\]. Recurrence is the main factor to be highlighted in the postoperative follow-up of these patients \[[@B3], [@B9]\].

The average time for the first local recurrence varies between 39 and 45 months \[[@B6], [@B7]\]. If the growth rate of the tumor is higher than 1 cm/month, it is related to a major incidence of recurrence, the average described in the literature being 0.34 cm/month \[[@B6], [@B10]\].

The gold-standard treatment is surgical resection \[[@B11]\]. In unresectable tumors, there is no consensus in the literature about the best treatment option \[[@B12]\]. Treatment with gemcitabine- and docetaxel-based regimens demonstrated a clinical response up to 40% in high-grade soft-tissue sarcomas \[[@B11], [@B12], [@B13], [@B14]\].

This study has the purpose of reporting the case of an individual with WD liposarcoma with early recurrence and a high growth rate (5.3 cm/month) yet with a complete response to gemcitabine- and docetaxel-based adjuvant first-line chemotherapy.

Case Presentation {#sec1_2}
=================

A 42-year-old female was admitted to an oncological service in January 2015 due to the presence of a lipomatous mass in the retroperitoneal area (T2bNXM0) observed in an abdominal computed tomography (CT) (Fig. [1a](#F1){ref-type="fig"}). The patient underwent a complete surgery in March of the same year.

The histopathological analysis of the specimen showed a tumor mass weighing 679 g and measuring 14.0 × 10.0 × 7.0 cm, partially encapsulated, formed by a trabeculated and fibroelastic, shinny brown-yellow tissue with central cystifications (Fig. [2](#F2){ref-type="fig"}) and the proliferation of lipoblast-like cells and hypercellular areas, with pleomorphic cells of bizarre hyperchromatic nuclear figures with both poorly and well-differentiated areas. Immunohistochemical stains were positive for the expression of S-100, ki-67, MDM2, and CDK4 proteins, consistent with WD liposarcoma (Fig. [3a, b](#F3){ref-type="fig"}).

In June 2015, the patient was submitted to a CT (Fig. [1b](#F1){ref-type="fig"}) showing an expansive lipogenic retroperitoneal mass involving the posterior pararenal space, measuring 8.0 × 16.0 × 7.7 cm in the biggest diameter with fibrous tissue and septations. The expansive effect determined the anterior displacement of the renal parenchyma and the compression of the iliopsoas muscle.

Thereafter, the patient underwent a new excision of the tumor, and the histopathological examination presented a high-grade pleomorphic sarcoma (Fig. [3b](#F3){ref-type="fig"}) that weighed 486 g and measured 14.0 × 12.0 × 6.0 cm, evidencing a growth rate of 5.3 cm/month. Due to the recurrence, the patient was initiated on a first-line chemotherapy regimen of gemcitabine (675 mg/m^2^) and docetaxel (100 mg/m^2^) for 8 cycles, during which she developed toxicity grade 2 (headache). Complete remission was demonstrated by an abdominal CT follow-up after the 8th cycle (Fig. [1c](#F1){ref-type="fig"}). The patient is currently monitored through clinical follow-up with the oncology service and imaging scans showing no evidence of recurrent disease 8 months after the last cycle of chemotherapy.

Discussion {#sec1_3}
==========

Time to relapse of the tumor in this report was only 3 months, while most of the studies observed 39--45 months for the first local relapse after surgery for WD liposarcoma \[[@B6], [@B7]\]. Another indispensable factor for the prognosis in this type of tumor is its growth rate, which was 5.3 cm/month in our patient; a value 15 times bigger compared to what is described in the literature (0.34 cm/month) \[[@B10]\]. Once a WD liposarcoma has a low growth rate and a relatively long time until relapse, it is considered more aggressive \[[@B5], [@B15]\].

Surgery is considered the first-line treatment for WD liposarcoma. For patients with inoperable tumors, the prognosis depends on adjuvant treatments that are controversial discussed among authors \[[@B11], [@B12], [@B13], [@B14]\]. First-line standard adjuvant chemotherapy with doxorubicin and ifosfamide shows a myriad of toxic effects, thus limiting its use. The second-line option is treatment with gemcitabine and docetaxel, which has demonstrated a complete clinical response in 30--45% of the cases in high-grade sarcomas and being the first-line therapy in the present report \[[@B11], [@B12], [@B13], [@B14]\]. Despite this tendency in the literature, this regimen\'s complete clinical response is still not well described \[[@B13], [@B14], [@B15]\]. Thus, the complete response observed in this report suggests the priorization of this therapy as a first-line adjuvant chemotherapy \[[@B13], [@B14], [@B15]\].

Facing all discussed points, the present case is atypical when compared to the ones in the current literature because the tumor presented a short relapse time and a very high growth rate. Besides, as complete response was obtained after the first-line adjuvant chemotherapy with gemcitabine and docetaxel, which is described as controversial in the literature, further studies for a better understanding of the lines of treatment for this type of tumor are recommended. On the other hand, the debate is challenged by the rarity of the disease.
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